{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:59:52Z","timestamp":1783043992322,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To describe the course of symptoms reported by patients with symptoms attributed to Lyme borreliosis (LB) without being subsequently diagnosed with LB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a prospective cohort study with patients presenting at the outpatient clinic of two clinical LB centres. The primary outcome was the prevalence of persistent symptoms, which were defined as clinically relevant fatigue (CIS, subscale fatigue), pain (SF-36, subscale bodily pain), and cognitive impairment (CFQ) for\u2009\u2265\u20096\u00a0months and onset\u2009&lt;\u20096\u00a0months over the first year of follow-up. Outcomes were compared with a longitudinal cohort of confirmed LB patients and a general population cohort. Prevalences were standardised to the distribution of pre-defined confounders in the confirmed LB cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants (<jats:italic>n<\/jats:italic>\u2009=\u2009123) reported mostly fatigue, arthralgia, myalgia, and paraesthesia as symptoms. The primary outcome could be determined for 74.8% (92\/123) of participants. The standardised prevalence of persistent symptoms in our participants was 58.6%, which was higher than in patients with confirmed LB at baseline (27.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and the population cohort (21.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Participants reported overall improvement of fatigue (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and pain (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) but not for cognitive impairment (<jats:italic>p<\/jats:italic>\u2009=\u20090.062) during the follow-up, though symptom severity at the end of follow-up remained greater compared to confirmed LB patients (various comparisons <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with symptoms attributed to LB who present at clinical LB centres without physician-confirmed LB more often report persistent symptoms and report more severe symptoms compared to confirmed LB patients and a population cohort.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-024-04770-6","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T13:01:46Z","timestamp":1710594106000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation and 1-year follow-up of patients presenting at a Lyme borreliosis expertise centre: a prospective cohort study with validated questionnaires"],"prefix":"10.1007","volume":"43","author":[{"given":"F. R.","family":"van de Schoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Baarsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Gauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ursinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. D.","family":"Vrijmoeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. M.","family":"ter Hofstede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Tulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"van den Wijngaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A. B.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Hovius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Kullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"4770_CR1","doi-asserted-by":"publisher","unstructured":"Ursinus J, Vrijmoeth HD, Harms MG, Tulen AD, Knoop H, Gauw SA, et al. (2021) Prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study. The Lancet Regional Health - Europe. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100142","DOI":"10.1016\/j.lanepe.2021.100142"},{"issue":"8","key":"4770_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41584-021-00648-5","volume":"17","author":"RB Lochhead","year":"2021","unstructured":"Lochhead RB, Strle K, Arvikar SL, Weis JJ, Steere AC (2021) Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol 17(8):449\u2013461","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"4770_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaad.2015.10.046","volume":"74","author":"C Lenormand","year":"2016","unstructured":"Lenormand C, Jaulhac B, Debarbieux S, Dupin N, Granel-Brocard F, Adamski H et al (2016) Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): a prospective study of 20 culture- and\/or polymerase chain reaction (PCR)-documented cases. J Am Acad Dermatol 74(4):685\u2013692","journal-title":"J Am Acad Dermatol"},{"key":"4770_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089\u20131134","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4770_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/eurpub\/ckv091","volume":"25","author":"CC van den Wijngaard","year":"2015","unstructured":"van den Wijngaard CC, Hofhuis A, Harms MG, Haagsma JA, Wong A, de Wit GA et al (2015) The burden of Lyme borreliosis expressed in disability-adjusted life years. Eur J Pub Health 25(6):1071\u20131078","journal-title":"Eur J Pub Health"},{"key":"4770_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1041","volume":"369","author":"BJ Kullberg","year":"2020","unstructured":"Kullberg BJ, Vrijmoeth HD, van de Schoor F, Hovius JW (2020) Lyme borreliosis: diagnosis and management. BMJ 369:m1041","journal-title":"BMJ"},{"issue":"4","key":"4770_CR7","doi-asserted-by":"publisher","first-page":"368 e11","DOI":"10.1016\/j.cmi.2014.11.014","volume":"21","author":"J Coumou","year":"2015","unstructured":"Coumou J, Herkes EA, Brouwer MC, van de Beek D, Tas SW, Casteelen G et al (2015) Ticking the right boxes: classification of patients suspected of Lyme borreliosis at an academic referral center in the Netherlands. Clin Microbiol Infect 21(4):368 e11\u201320","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4770_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cmi.2020.09.022","volume":"27","author":"E Kortela","year":"2021","unstructured":"Kortela E, Kanerva M, Kurkela S, Oksi J, Jarvinen A (2021) Suspicion of Lyme borreliosis in patients referred to an infectious diseases clinic: what did the patients really have? Clin Microbiol Infect 27(7):1022\u20131028","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"4770_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2020.101591","volume":"12","author":"RMM Gynthersen","year":"2021","unstructured":"Gynthersen RMM, Tetens MM, Orbaek M, Haahr R, Fana V, Hansen K et al (2021) Classification of patients referred under suspicion of tick-borne diseases, Copenhagen, Denmark. Ticks Tick Borne Dis 12(1):101591","journal-title":"Ticks Tick Borne Dis"},{"issue":"12","key":"4770_CR10","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1093\/cid\/ciy799","volume":"68","author":"E Haddad","year":"2019","unstructured":"Haddad E, Chabane K, Jaureguiberry S, Monsel G, Pourcher V, Caumes E (2019) Holistic approach in patients with presumed Lyme borreliosis leads to less than 10% of confirmation and more than 80% of antibiotic failures. Clin Infect Dis 68(12):2060\u20132066","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4770_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.medmal.2018.06.002","volume":"49","author":"C Jacquet","year":"2019","unstructured":"Jacquet C, Goehringer F, Baux E, Conrad JA, Ganne Devonec MO, Schmutz JL et al (2019) Multidisciplinary management of patients presenting with Lyme disease suspicion. Med Mal Infect 49(2):112\u2013120","journal-title":"Med Mal Infect"},{"issue":"6","key":"4770_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/qjmed\/hcs003","volume":"105","author":"LE Cottle","year":"2012","unstructured":"Cottle LE, Mekonnen E, Beadsworth MB, Miller AR, Beeching NJ (2012) Lyme disease in a British referral clinic. QJM 105(6):537\u2013543","journal-title":"QJM"},{"issue":"4","key":"4770_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1468-1331.2010.03229.x","volume":"18","author":"M Djukic","year":"2011","unstructured":"Djukic M, Schmidt-Samoa C, Nau R, von Steinbuchel N, Eiffert H, Schmidt H (2011) The diagnostic spectrum in patients with suspected chronic Lyme neuroborreliosis\u2013the experience from one year of a university hospital\u2019s Lyme neuroborreliosis outpatients clinic. Eur J Neurol 18(4):547\u2013555","journal-title":"Eur J Neurol"},{"issue":"1","key":"4770_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cmi.2018.09.016","volume":"25","author":"TP Zomer","year":"2019","unstructured":"Zomer TP, Barendregt JNM, van Kooten B, van Bemmel T, Landman GW, van Hees BC et al (2019) Non-specific symptoms in adult patients referred to a Lyme centre. Clin Microbiol Infect 25(1):67\u201370","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4770_CR15","doi-asserted-by":"publisher","first-page":"ofz299","DOI":"10.1093\/ofid\/ofz299","volume":"6","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Higgins Y, Samuels R, Moaven A, Sanyal A, Yenokyan G et al (2019) Misdiagnosis of Lyme disease with unnecessary antimicrobial treatment characterizes patients referred to an academic infectious diseases clinic. Open Forum Infect Dis 6(7):ofz299","journal-title":"Open Forum Infect Dis"},{"key":"4770_CR16","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Higgins Y, Melia MT, Auwaerter PG (2021) Mistaken identity: many diagnoses are frequently misattributed to Lyme disease. Am J Med. https:\/\/doi.org\/10.1016\/j.amjmed.2021.10.040","DOI":"10.1016\/j.amjmed.2021.10.040"},{"issue":"5","key":"4770_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7326\/0003-4819-128-5-199803010-00003","volume":"128","author":"MC Reid","year":"1998","unstructured":"Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI (1998) The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 128(5):354\u2013362","journal-title":"Ann Intern Med"},{"issue":"1","key":"4770_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12879-019-4323-6","volume":"19","author":"FR van de Schoor","year":"2019","unstructured":"van de Schoor FR, Baarsma ME, Gauw SA, Joosten LAB, Kullberg BJ, van den Wijngaard CC et al (2019) Validation of cellular tests for Lyme borreliosis (VICTORY) study. BMC Infect Dis 19(1):732","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4770_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12879-019-3949-8","volume":"19","author":"HD Vrijmoeth","year":"2019","unstructured":"Vrijmoeth HD, Ursinus J, Harms MG, Zomer TP, Gauw SA, Tulen AD et al (2019) Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect). BMC Infect Dis 19(1):324","journal-title":"BMC Infect Dis"},{"key":"4770_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jpsychores.2017.05.007","volume":"98","author":"M Worm-Smeitink","year":"2017","unstructured":"Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P et al (2017) The assessment of fatigue: psychometric qualities and norms for the checklist individual strength. J Psychosom Res 98:40\u201346","journal-title":"J Psychosom Res"},{"issue":"11","key":"4770_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Cohen PDA, Essink-Bot M-L, Fekkes M, Sanderman R et al (1998) Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055\u20131068","journal-title":"J Clin Epidemiol"},{"key":"4770_CR22","first-page":"37","volume":"2","author":"R Ponds","year":"2006","unstructured":"Ponds R, Van Boxtel M, Jolles J (2006) De Cognitive Failure Questionnaire als maat voor subjectief cognitief functioneren. Tijdschrift voor neuropsychologie 2:37\u201345","journal-title":"Tijdschrift voor neuropsychologie"},{"key":"4770_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1472-6963-13-217","volume":"13","author":"C Bouwmans","year":"2013","unstructured":"Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-Cornelis C, Tan Swan S et al (2013) Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res 13:217","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"4770_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","volume":"17","author":"G Stanek","year":"2011","unstructured":"Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A et al (2011) Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 17(1):69\u201379","journal-title":"Clin Microbiol Infect"},{"issue":"1_suppl","key":"4770_CR25","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1177\/0022146510383495","volume":"51","author":"P Conrad","year":"2010","unstructured":"Conrad P, Barker KK (2010) The social construction of illness: key insights and policy implications. J Health Soc Behav 51(1_suppl):S67\u2013S79","journal-title":"J Health Soc Behav"},{"key":"4770_CR26","doi-asserted-by":"publisher","unstructured":"Baarsma ME FRvdS, Stefanie A Gauw, Hedwig D Vrijmoeth, Jeanine Ursinus, Nienke Goudriaan, Calin D Popa, Hadewych JM ter Hofstede, Mariska MG Leeflang, Kristin Kremer, Cees C van den Wijngaard, Bart-Jan Kullberg, Leo AB Joosten, Joppe W Hovius (2022) Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study. The Lancet Infectious Diseases. https:\/\/doi.org\/10.1016\/S1473-3099(22)00205-5","DOI":"10.1016\/S1473-3099(22)00205-5"},{"key":"4770_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100344","volume":"15","author":"CC van den Wijngaard","year":"2022","unstructured":"van den Wijngaard CC, Ursinus J, Vrijmoeth HD, Knoop H, Wong A, Joosten LAB et al (2022) Concerns about the external validity of the study \u2018prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study\u2019-authors\u00b4 reply. The Lancet Regional Health - Europe 15:100344","journal-title":"The Lancet Regional Health - Europe"},{"issue":"1","key":"4770_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12875-022-01736-5","volume":"23","author":"ME Baarsma","year":"2022","unstructured":"Baarsma ME, Claassen SA, van der Horst HE, Hovius JW, Sanders JM (2022) Knowing the entire story - a focus group study on patient experiences with chronic Lyme-associated symptoms (chronic Lyme disease). BMC Prim Care 23(1):139","journal-title":"BMC Prim Care"},{"key":"4770_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2296-15-79","volume":"15","author":"A Ali","year":"2014","unstructured":"Ali A, Vitulano L, Lee R, Weiss TR, Colson ER (2014) Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study. BMC Fam Pract 15:79","journal-title":"BMC Fam Pract"},{"issue":"10","key":"4770_CR30","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s11136-018-1918-0","volume":"27","author":"A Hinz","year":"2018","unstructured":"Hinz A, Weis J, Brahler E, Mehnert A (2018) Fatigue in the general population: German normative values of the EORTC QLQ-FA12. Qual Life Res 27(10):2681\u20132689","journal-title":"Qual Life Res"},{"issue":"1","key":"4770_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/j.pain.0000000000000314","volume":"157","author":"KE Mansfield","year":"2016","unstructured":"Mansfield KE, Sim J, Jordan JL, Jordan KP (2016) A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain 157(1):55\u201364","journal-title":"Pain"},{"key":"4770_CR32","doi-asserted-by":"publisher","unstructured":"Raffetin A, Schemoul J, Chahour A, Nguala S, Caraux-Paz P, Paoletti G, et al. (2022) Multidisciplinary management of suspected Lyme borreliosis: clinical features of 569 patients, and factors associated with recovery at 3 and 12 months, a prospective cohort study. Microorganisms. 10(3). https:\/\/doi.org\/10.3390\/microorganisms10030607","DOI":"10.3390\/microorganisms10030607"},{"key":"4770_CR33","doi-asserted-by":"publisher","unstructured":"Marques A, Shaw P, Schmid CH, Steere A, Kaplan RF, Hassett A, et al. (2009) Re: A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Prolonged Lyme disease treatment: enough is enough. Neurology. 72(4):383\u20134; author reply 4. https:\/\/doi.org\/10.1212\/01.wnl.0000343855.45704.7c","DOI":"10.1212\/01.wnl.0000343855.45704.7c"},{"issue":"5","key":"4770_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jpsychores.2008.09.018","volume":"66","author":"TC Olde Hartman","year":"2009","unstructured":"Olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C (2009) Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis A systematic review. J Psychosomat Res 66(5):363\u201377","journal-title":"J Psychosomat Res"},{"key":"4770_CR35","first-page":"D1680","volume":"161","author":"DJC Hanssen","year":"2017","unstructured":"Hanssen DJC, Knoop H, Rosmalen JGM (2017) The prognosis of medically unexplained symptoms. Ned Tijdschr Geneeskd 161:D1680","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"5","key":"4770_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.medmal.2019.10.011","volume":"50","author":"M Voitey","year":"2020","unstructured":"Voitey M, Bouiller K, Chirouze C, Fournier D, Bozon F, Klopfenstein T (2020) Functional signs in patients consulting for presumed Lyme borreliosis. Med Mal Infect 50(5):423\u2013427","journal-title":"Med Mal Infect"},{"issue":"9","key":"4770_CR37","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S1473-3099(22)00205-5","volume":"22","author":"ME Baarsma","year":"2022","unstructured":"Baarsma ME, van de Schoor FR, Gauw SA, Vrijmoeth HD, Ursinus J, Goudriaan N et al (2022) Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study. Lancet Infect Dis 22(9):1388\u20131396","journal-title":"Lancet Infect Dis"},{"key":"4770_CR38","unstructured":"(NICE); NIfHaCE. Myalgic encephalomyelitis (or encephalopathy)\/chronic fatigue syndrome: diagnosis and management. Available from: https:\/\/wwwniceorguk\/guidance\/ng206"},{"key":"4770_CR39","doi-asserted-by":"publisher","unstructured":"Galvez-S\u00e1nchez CM, Reyes Del Paso GA (2020) Diagnostic criteria for fibromyalgia: critical review and future perspectives. J Clin Med 9(4). https:\/\/doi.org\/10.3390\/jcm9041219","DOI":"10.3390\/jcm9041219"},{"issue":"5","key":"4770_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","volume":"28","author":"J Choutka","year":"2022","unstructured":"Choutka J, Jansari V, Hornig M, Iwasaki A (2022) Unexplained post-acute infection syndromes. Nat Med 28(5):911\u2013923","journal-title":"Nat Med"},{"key":"4770_CR41","doi-asserted-by":"publisher","unstructured":"Burton C, Fink P, Henningsen P, L\u00f6we B, Rief W, on behalf of the E-SG (2020) Functional somatic disorders: discussion paper for a new common classification for research and clinical use. BMC Med 18(1):34. https:\/\/doi.org\/10.1186\/s12916-020-1505-4","DOI":"10.1186\/s12916-020-1505-4"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T09:09:22Z","timestamp":1716282562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["4770"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04770-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have received any financial compensation from any of the companies participating in the study. MEB and JWH collaborate with Abbott, Bio-Rad Laboratories, and ZEUS Scientific. Moderna and Pfizer on unrelated projects on LB. FvdS and LABJ collaborate with Hycult Biotech on developing novel diagnostic tests for LB. BJK and LABJ are co-inventors of the Spirofind, an experimental in-house assay for LB, which is owned by Radboudumc and was previously licensed for development to Boulder Diagnostics (Boulder, CO, USA) and subsequently Oxford Immunotec (Oxford, UK) until 2018. The other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}